Genomic and expression profiling of adrenocortical carcinoma: Application to diagnosis, prognosis and treatment

Future Oncology

Volumn 5, Issue 5, 2009, Pages 641-655

  Bussey, Kimberly J ^a   Demeure, Michael J ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Adrenocortical carcinoma; Cell cycle; Expression profiling; Genomic profiling; IGF2; Mitotane; P53

Indexed keywords

BCR ABL PROTEIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MITOTANE; PROTEIN P53; PROTEIN P57; SOMATOMEDIN;

ADJUVANT THERAPY; ADRENAL CORTEX CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHROMOSOME ANALYSIS; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENOMICS; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTOMICS; UNSPECIFIED SIDE EFFECT; ADRENAL CORTEX TUMOR; GENETICS;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS;

EID: 69849087670     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.45     Document Type: Review

References (71)

1. Greenberg PH, Marks C: Adrenal cortical carcinoma: a presentation of 22 cases and a review of the literature. Am. Surg. 44, 81-85 (1978).
2. Karakousis CP, Rao U, Moore R: Adrenal adenocarcinomas: histologic grading and survival. J. Surg. Oncol. 29, 105-111 (1985).
3. Kjellman M, Kallioniemi OP, Karhu R et al.: Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 56, 4219-4223 (1996).
4. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA: Adrenal cortical carcinoma. Cancer 64, 765-769 (1989).
5. Thompson NW, Cheung PS: Diagnosis and treatment of functioning and nonfunctioning adrenocortical neoplasms including incidentalomas. Surg. Clin. North Am. 67, 423-436 (1987).
6. Libe R, Fratticci A, Bertherat J: Adrenocortical cancer: pathophysiology and clinical management. Endocr. Relat. Cancer 14, 13-28 (2007).
7. Dohna M, Reincke M, Mincheva A et al.: Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28, 145-152 (2000).
8. Sidhu S, Marsh DJ, Theodosopoulos G et al.: Comparative genomic hybridization analysis of adrenocortical tumors. J. Clin. Endocrinol. Metab. 87, 3467-3474 (2002).
9. Zhao J, Roth J, Bode-Lesniewska B et al.: Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 34, 48-57 (2002).
10. Zhao J, Speel EJ, Muletta-Feurer S et al.: Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am. J. Pathol. 155, 1039-1045 (1999).
11. Stephan EA, Chung TH, Grant CS et al.: Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol. Cancer Ther. 7, 425-431 (2008).
12. Figueiredo BC, Stratakis CA, Sandrini R et al.: Comparative genomic hybridization ana lysis of adrenocortical tumors of childhood. J. Clin. Endocrinol. Metab. 84, 1116-1121 (1999).
13. James LA, Kelsey AM, Birch JM, Varley JM: Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization. Br. J. Cancer 81, 300-304 (1999).
14. de Fraipont F, El Atifi M, Cherradi N et al.: Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 90, 1819-1829 (2005).
15. Giordano TJ, Thomas DG, Kuick R et al.: Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 162, 521-531 (2003).
16. Slater EP, Diehl SM, Langer P et al.: Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur. J. Endocrinol. 154, 587-598 (2006).
17. Velazquez-Fernandez D, Laurell C, Geli J et al.: Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138, 1087-1094 (2005).
18. West AN, Neale GA, Pounds S et al.: Gene expression profiling of childhood adrenocortical tumors. Cancer Res. 67, 600-608 (2007).
19. de Reynies A, Assie G, Rickman DS et al.: Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108-1115 (2009).
20. Giordano TJ, Kuick R, Else T et al.: Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15, 668-676 (2009).
21. Soon P, Gill A, Benn D et al.: Microarray gene expression and immunohistochemistry analyses of adrenocortical tumours identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr. Relat. Cancer 2009 (Epub ahead of print.)
22. Cohn K, Gottesman L, Brennan M: Adrenocortical carcinoma. Surgery 100, 1170-1177 (1986).
23. Lee JE, Berger DH, el-Naggar AK et al.: Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118, 1090-1098 (1995).
24. Didolkar MS, Bescher RA, Elias EG, Moore RH: Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 47, 2153-2161 (1981).
25. Martz F, Straw JA: The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab. Dispos. 5, 482-486 (1977).
26. Martz F, Straw JA: Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Drug Metab. Dispos. 8, 127-130 (1980).
27. Lindhe O, Skogseid B, Brandt I: Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/ reticularis. J. Clin. Endocrinol. Metab. 87, 1319-1326 (2002).
28. Schteingart DE, Sinsheimer JE, Counsell RE et al.: Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Cancer Chemother. Pharmacol. 31, 459-466 (1993).
29. Stigliano A, Cerquetti L, Borro M et al.: Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr. Relat. Cancer 15, 1-10 (2008).
30. Bergenstal DM, Lipsett M, Moy RN, Hertz R: Regression of adrenal cancer and suppression of adrenal function in man by o,p'-DDD. Trans. Am. Physicians 72, 341-350 (1959).
31. Haak HR, Hermans J, van de Velde CJ et al.: Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br. J. Cancer 69, 947-951 (1994).
32. Pommier RF, Brennan MF: An eleven-year experience with adrenocortical carcinoma. Surgery 112, 963-970; discussion 970-971 (1992).
33. Stojadinovic A, Ghossein RA, Hoos A et al.: Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J. Clin. Oncol. 20, 941-950 (2002).
34. Terzolo M, Angeli A, Fassnacht M et al.: Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356, 2372-2380 (2007).
35. Decker RA, Elson P, Hogan TF et al.: Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110, 1006-1013 (1991).
36. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D: The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur. J. Cancer Clin. Oncol. 20, 47-53 (1984).
37. Barzon L, Fallo F, Sonino N, Daniele O, Boscaro M: Comment - is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J. Clin. Endocrinol. Metab. 84, 1488-1489 (1999).
38. Vassilopoulou-Sellin R, Guinee VF, Klein MJ et al.: Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71, 3119-3123 (1993).
39. Berruti A, Terzolo M, Sperone P et al.: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr. Relat. Cancer 12, 657-666 (2005).
40. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747-749 (1990).
41. Olivier M, Goldgar DE, Sodha N et al.: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 63, 6643-6650 (2003).
42. Zambetti GP: The p53 mutation 'gradient effect' and its clinical implications. J. Cell Physiol. 213, 370-373 (2007).
43. Ignaszak-Szczepaniak M, Horst-Sikorska W, Sawicka J, Kaczmarek M, Slomski R: The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients. Oncol. Rep. 16, 65-71 (2006).
44. Blake JA, Bult CJ, Eppig JT, Kadin JA, Richardson JE: The Mouse Genome Database genotypes:phenotypes. Nucleic Acids Res. 37, D712-D719 (2009).
45. Bult CJ, Eppig JT, Kadin JA, Richardson JE, Blake JA: The Mouse Genome Database (MGD): mouse biology and model systems. Nucleic Acids Res. 36, D724-D728 (2008).
46. Sakatani T, Kaneda A, Iacobuzio-Donahue CA et al.: Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307, 1976-1978 (2005).
47. Moorehead RA, Fata JE, Johnson MB, Khokha R: Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ. 8, 16-29 (2001).
48. Weksberg R, Nishikawa J, Caluseriu O et al.: Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum. Mol. Genet. 10, 2989-3000 (2001).
49. Else T, Giordano TJ, Hammer GD: Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 93, 1442-1449 (2008).
50. Lu Q, Dobbs LJ, Gregory CW et al.: Increased expression of δ-catenin/neural plakophilin-related armadillo protein is associated with the downregulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum. Pathol. 36, 1037-1048 (2005).
51. Krupke DM, Begley DA, Sundberg JP, Bult CJ, Eppig JT: The Mouse Tumor Biology Database. Nat. Rev. Cancer 8, 459-465 (2008).
52. Boyd MR, Paull KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34, 91-109 (1995).
53. Shoemaker RH, Monks A, Alley MC et al.: Development of human tumor cell line panels for use in disease-oriented drug screening. Prog. Clin. Biol. Res. 276, 265-286 (1988).
54. Ross DT, Scherf U, Eisen MB et al.: Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227-235 (2000).
55. Scherf U, Ross DT, Waltham M et al.: A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236-244 (2000).
56. Staunton JE, Slonim DK, Coller HA et al.: Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98, 10787-10792 (2001).
57. Li G, Waltham M, Anderson NL, Unsworth E, Treston A, Weinstein JN: Rapid mass spectrometric identification of proteins from two-dimensional polyacrylamide gels after in gel proteolytic digestion. Electrophoresis 18, 391-402 (1997).
58. Myers TG, Anderson NL, Waltham M et al.: A protein expression database for the molecular pharmacology of cancer. Electrophoresis 18, 647-653 (1997).
59. Nishizuka S, Charboneau L, Young L et al.: Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100, 14229-14234 (2003).
60. Nishizuka S, Chen ST, Gwadry FG et al.: Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63, 5243-5250 (2003).
61. Bussey KJ, Chin K, Lababidi S et al.: Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 5, 853-867 (2006).
62. Roschke AV, Tonon G, Gehlhaus KS et al.: Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 63, 8634-8647 (2003).
63. Lorenzi PL, Reinhold WC, Rudelius M et al.: Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol. Cancer Ther. 5, 2613-2623 (2006).
64. Potti A, Dressman HK, Bild A et al.: Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12, 1294-1300 (2006).
65. Bettio D, Rizzi N, Giardino D et al.: Translocation (7;17)(q22;p13) as a sole karyotypic change in an adrenal adenoma. Cancer Genet. Cytogenet. 103, 180-181 (1998).
66. Gordon RD, Stowasser M, Martin N et al.: Karyotypic abnormalities in benign adrenocortical tumors producing aldosterone. Cancer Genet. Cytogenet. 68, 78-81 (1993).
67. Herrmann ME, Rydstedt LL, Talpos GB et al.: Chromosomal aberrations in two adrenocortical tumors, one with a rearrangement at 11p15. Cancer Genet. Cytogenet. 75, 111-116 (1994).
68. Limon J, Dal Cin P, Kakati S, Huben RP, Rao U, Sandberg AA: Cytogenetic findings in a primary adrenocortical carcinoma. Cancer Genet. Cytogenet. 26, 271-277 (1987).
69. Limon J, Dal Cin P, Gaeta J, Sandberg AA: Translocation t(4;11)(q35;p13) in an adrenocortical carcinoma. Cancer Genet. Cytogenet. 28, 343-348 (1987).
70. Marks JL, Wyandt HE, Beazley RM et al.: Cytogenetic studies of an adrenal cortical carcinoma. Cancer Genet. Cytogenet. 61, 96-98 (1992).
71. Mertens F, Kullendorff C-M, Moell C, Alumets J, Mandahl N: Complex karyotype in a childhood adrenocortical carcinoma. Cancer Genet. Cytogenet. 105, 190-192 (1998).